XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Stock-based Compensation Expense
The stock-based compensation related to our stock-based awards and employee stock purchase plan for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Cost of net revenues$1,974 $1,651 $5,682 $4,779 
Selling, general and administrative29,739 25,293 87,432 76,509 
Research and development7,889 5,974 22,083 17,391 
Total stock-based compensation$39,602 $32,918 $115,197 $98,679 
Summary Of Restricted Stock Units A summary for the nine months ended September 30, 2023 is as follows:
Number of Shares
Underlying RSUs
(in thousands)
Weighted Average Grant Date Fair ValueWeighted Average Remaining
Contractual Term (in years)		Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2022
489 $427.24 
Granted
508 316.52 
Vested and released(196)378.93 
Forfeited(37)388.56 
Unvested as of September 30, 2023
764 $367.93 1.6$233,165 
Summary Of Market-performance Based Restricted Stock Units
The following table summarizes the MSU performance activity for the nine months ended September 30, 2023: 
Number of Shares
Underlying MSUs
(in thousands)
Weighted Average Grant Date Fair Value
Weighted Average
Remaining
Contractual Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2022
144 $725.73 
Granted82 629.53 
Vested and released 1
(25)392.67 
Forfeited(43)423.87 
Unvested as of September 30, 2023
158 $811.06 1.7$48,135 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:
 Nine Months Ended
September 30,
 20232022
Expected term (in years)1.21.5
Expected volatility56.2 %50.2 %
Risk-free interest rate4.9 %1.8 %
Expected dividends— — 
Weighted average fair value at grant date$133.53 $159.44